Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Letizia Musumeci

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Dermatologic Therapy|February 23, 2021
DECISA Project (DErmatology Clinics in Italy: Survey on Alitretinoin): A real-life retrospective cohort multicenter study on 438 subjects with chronic hand eczemaSilvia Ferrucci, Paola Persichini, Massimo Gola, et al.
Acta Dermato-Venereologica|April 27, 2021
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME StudyAntonio Costanzo, Filomena Russo, Marco Galluzzo, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|May 7, 2026
Real-Life Effectiveness, Safety, and Growth Outcomes of Dupilumab in Children Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis: A Multicenter Retrospective Study from an Italian NPP ProgramMaddalena Napolitano, Giuseppe Lauletta, Martina Turco, et al.
Journal of Clinical Medicine|May 27, 2023
Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus StatementMaria Concetta Fargnoli, Federico Bardazzi, Luca Bianchi, et al.
Plos One|August 14, 2020
Patients' demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasisEmanuele Scala, Matteo Megna, Paolo Amerio, et al.
Dermatology and Therapy|July 24, 2025
JAK Inhibitors in Atopic Dermatitis: Does Weight Matter? A Real-World, Nationwide Retrospective Study: IL-AD (Italian Landscape Atopic Dermatitis)Mariateresa Rossi, Stefano Bighetti, Alessandra Narcisi, et al.
Clinical, Cosmetic and Investigational Dermatology|December 18, 2023
Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 StudyFilomena Russo, Marco Galluzzo, Luca Stingeni, et al.
Journal of Clinical Medicine|February 26, 2025
Effectiveness of Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: A Retrospective, Real-World Multicenter Study with a Focus on Obese and Multi-Failure Patients-IL PSO (Italian Landscape Psoriasis)Diego Orsini, Dario Graceffa, Martina Burlando, et al.
Clinical and Experimental Dermatology|June 11, 2024
Short-, mid- and long-term efficacy of dupilumab in moderate-to-severe atopic dermatitis: a real-world multicentre Italian study of 2576 patientsSilvia Ferrucci, Simona Tavecchio, Carlo Alberto Maronese, et al.
Clinical and Experimental Dermatology|October 30, 2025
Psoriasis and Seronegative Spondyloarthropathy in Atopic Dermatitis Patients Treated with Dupilumab or Tralokinumab: A Multicentre Observational StudyGiuseppe Lauletta, Cataldo Patruno, Luca Potestio, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Dermatologic Therapy|February 23, 2021
DECISA Project (DErmatology Clinics in Italy: Survey on Alitretinoin): A real-life retrospective cohort multicenter study on 438 subjects with chronic hand eczemaSilvia Ferrucci, Paola Persichini, Massimo Gola, et al.
Acta Dermato-Venereologica|April 27, 2021
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME StudyAntonio Costanzo, Filomena Russo, Marco Galluzzo, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|May 7, 2026
Real-Life Effectiveness, Safety, and Growth Outcomes of Dupilumab in Children Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis: A Multicenter Retrospective Study from an Italian NPP ProgramMaddalena Napolitano, Giuseppe Lauletta, Martina Turco, et al.
Journal of Clinical Medicine|May 27, 2023
Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus StatementMaria Concetta Fargnoli, Federico Bardazzi, Luca Bianchi, et al.
Plos One|August 14, 2020
Patients' demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasisEmanuele Scala, Matteo Megna, Paolo Amerio, et al.
Dermatology and Therapy|July 24, 2025
JAK Inhibitors in Atopic Dermatitis: Does Weight Matter? A Real-World, Nationwide Retrospective Study: IL-AD (Italian Landscape Atopic Dermatitis)Mariateresa Rossi, Stefano Bighetti, Alessandra Narcisi, et al.
Clinical, Cosmetic and Investigational Dermatology|December 18, 2023
Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 StudyFilomena Russo, Marco Galluzzo, Luca Stingeni, et al.
Journal of Clinical Medicine|February 26, 2025
Effectiveness of Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: A Retrospective, Real-World Multicenter Study with a Focus on Obese and Multi-Failure Patients-IL PSO (Italian Landscape Psoriasis)Diego Orsini, Dario Graceffa, Martina Burlando, et al.
Clinical and Experimental Dermatology|June 11, 2024
Short-, mid- and long-term efficacy of dupilumab in moderate-to-severe atopic dermatitis: a real-world multicentre Italian study of 2576 patientsSilvia Ferrucci, Simona Tavecchio, Carlo Alberto Maronese, et al.
Clinical and Experimental Dermatology|October 30, 2025
Psoriasis and Seronegative Spondyloarthropathy in Atopic Dermatitis Patients Treated with Dupilumab or Tralokinumab: A Multicentre Observational StudyGiuseppe Lauletta, Cataldo Patruno, Luca Potestio, et al.
Pageof 6